In previous studies, we have shown that steroid hormone resistance in New World primates occurs in the absence of abnormal expression of cognate nuclear receptors. Rather, these animals have elevated levels of heterogeneous nuclear ribonucleoproteins (hnRNPs) that act as hormone response element-binding proteins and attenuate target gene transactivation. Here we present evidence for a similar mechanism in humans via a patient with resistance to the active form of vitamin D [1,25-dihydroxyvitamin D3 (1,25(OH)2D3)] who presented with normal vitamin D receptor (VDR) expression. Initial cotransfection studies showed that the cells of the patient suppressed basal and hormone-induced transactivation by wild-type VDR. Electrophoretic mobility-shift assays and Western͞Southwestern blot analyses indicated that this suppressive effect was due to overexpression of a nuclear protein that specifically interacts with a DNA response element known to bind retinoid X receptor-VDR heterodimers. Ab blocking in electrophoretic mobility-shift assays indicated that this dominant-negative acting protein was in the hnRNPA family of nucleic acid-binding proteins. Further studies have shown that several members of this family, most notably hnRNPA1, were able to suppress basal and 1,25(OH)2D3-induced luciferase activity. We therefore propose that this case of vitamin D resistance in a human subject is similar to that previously described for New World primates in which abnormal expression of a hormone response element-binding protein can cause target cell resistance to 1,25(OH)2D3. That this protein is a member of the hnRNP family capable of interacting with doublestranded DNA highlights a potentially important new component of the complex machinery required for steroid hormone signal transduction.
In previous studies, we have shown that steroid hormone resistance in New World primates occurs in the absence of abnormal expression of cognate nuclear receptors. Rather, these animals have elevated levels of heterogeneous nuclear ribonucleoproteins (hnRNPs) that act as hormone response element-binding proteins and attenuate target gene transactivation. Here we present evidence for a similar mechanism in humans via a patient with resistance to the active form of vitamin D [1,25-dihydroxyvitamin D3 (1,25(OH)2D3)] who presented with normal vitamin D receptor (VDR) expression. Initial cotransfection studies showed that the cells of the patient suppressed basal and hormone-induced transactivation by wild-type VDR. Electrophoretic mobility-shift assays and Western͞Southwestern blot analyses indicated that this suppressive effect was due to overexpression of a nuclear protein that specifically interacts with a DNA response element known to bind retinoid X receptor-VDR heterodimers. Ab blocking in electrophoretic mobility-shift assays indicated that this dominant-negative acting protein was in the hnRNPA family of nucleic acid-binding proteins. Further studies have shown that several members of this family, most notably hnRNPA1, were able to suppress basal and 1,25(OH)2D3-induced luciferase activity. We therefore propose that this case of vitamin D resistance in a human subject is similar to that previously described for New World primates in which abnormal expression of a hormone response element-binding protein can cause target cell resistance to 1,25(OH)2D3. That this protein is a member of the hnRNP family capable of interacting with doublestranded DNA highlights a potentially important new component of the complex machinery required for steroid hormone signal transduction.
A nalysis of inherited forms of steroid hormone resistance has greatly helped to clarify the underlying mechanisms by which molecules such as cortisol, testosterone, estradiol, and vitamin D achieve their actions (1, 2) . In almost all cases, end organ resistance has been attributed to inactivating mutations of genes for intracellular steroid hormone receptors, despite the fact that a range of accessory proteins is required for steroid hormone signal transduction (3) (4) (5) . However, recent reports have described novel forms of hormone resistance that have presented in the absence of a specific receptor gene mutation. These include an androgen receptor (AR)-positive patient with androgen insensitivity syndrome whose hormone resistance seems to be due to abnormal expression of a coactivator protein that interacts with the AF-1 domain of the AR (6) . Accessory protein abnormality has also been proposed as the molecular defect in female siblings who presented with partial resistance to multiple steroid hormones (7) . In view of these observations, it is possible to speculate that other forms of hormone resistance may also be due to abnormal accessory protein expression and function (8, 9) .
We have shown that another class of proteins possibly acts as dominant-negative modulators of steroid hormone-mediated transcription. Heterogeneous nuclear ribonucleoproteins (hnRNPs) are a family of Ͼ20 proteins that contributes to the complex around nascent pre-mRNA and are thus able to modulate RNA processing (10) (11) (12) . The ability of hnRNPs to attenuate steroid hormone receptor gene transactivation has been demonstrated in studies of New World primates (NWPs) that are characterized by their relative target organ resistance to adrenal, gonadal, and vitamin D sterol͞steroid hormones (13) (14) (15) (16) (17) (18) (19) (20) . Data indicate that NWPs exhibit forms of receptor-normal resistance to vitamin D and estrogen that are due to overexpression of hnRNP-like dominant-negative-acting hormone response element (RE)-binding proteins (REBiPs; refs. [21] [22] [23] . The 42-kDa NWP estrogen REBiP is highly homologous to the hnRNPC subfamily (21, 22) . In addition we have purified two vitamin D RE (VDRE)-binding proteins (BPs) that show strong sequence homology to members of the human hnRNPA family (23) . In both cases, overexpression of the REBiP was able to squelch hormone-activated transcription via the appropriate RE. Therefore, we postulated that a similar molecular lesion could account for a receptor-normal vitamin D resistance in human as well as in nonhuman primates.
To address this hypothesis, we have characterized the molecular basis for end organ resistance in a patient who presented with skeletal abnormalities and biochemical features classically associated with vitamin D-resistant rickets. (24) . The patient was without evidence of any other form of steroid-thyroid-retinoid hormone resistance, and correction of rachitic bone disease was accomplished with high-dose 1,25(OH) 2 D 3 treatment (12 g͞day) and calcium supplements (1 g͞day), although the alopecia persisted. Here we show that the underlying cause of insensitivity to 1,25(OH) 2 D 3 in this patient is overexpression of a VDRE-interacting REBiP with similarity to the hnRNPA family. This study represents evidence for a human form of receptor-normal hormone resistance similar to that observed in NWPs. from a patient with classical symptoms of type II hereditary vitamin D-resistant rickets (HVDRRII) (24) Further cotransfection studies were carried out by using aliquots (5 g) of expression constructs for various REBiPs: VDRE-BP1 and VDRE-BP2 (both NWPs) and hnRNPA1 and hnRNPA2 (both human). An equal volume of 20% FCS-supplemented, antibiotic-free medium was added to each well 5 h after transfection followed by the addition of 10 nM 1,25(OH) 2 D 3 . After an additional 48 h at 37°C, the cells were lysed, and luciferase and ␤-galactosidase activities were measured.
Electrophoretic Mobility-Shift Assays (EMSAs). Preparation of nuclear extracts (NEs) was according to a modification (23) of the method of Zerivitz and Akusjarvi (25) . In some experiments, extracts were digested with trypsin. Sequences of the various oligonucleotides used were as follows (consensus recognition sequences are underlined): direct repeat VDRE with three nucleotides between half-sites (VDRE-D3), 5Ј-CTAGTGCTC-GGGTAGAGGTCACAGAGGTCACTCGACTCGT-3Ј;osteopontin VDRE (VDRE-OP), 5Ј-CTAGTGCTCGGGTAG-GGTTCACGAGGTTCACTCGACTCG-3; retinoid X RE (RXRE) with one nucleotide between half-sites, 5Ј-AGC-TTCAGGTCAGAGGTCAGAGAGCT-3Ј; chicken ovalbumin upstream promoter transcription factor 1 (COUP-TF1-RE), 5Ј-TTCTATGGTGTCAAAGGTCAAAC-3Ј; estrogen RE (ERE), 5Ј-CTAGAAAGTCAGGTCACAGTGACCTGAT-CAAT-3Ј; and nuclear factor yin-yang-1 RE (YY1-RE), 5Ј-CGCTCCGCGGCCATCTTGGCGGGTGG T-3Ј. EMSA was performed as described (21) (22) (23) .
Abs and Blotting Assays. A panel of Abs was used in supershift EMSA and in Western blot analyses. The panel included antihuman VDR (N-and C-terminal), anti-human retinoid X receptor (RXR)␣ and RXR␤ (all from Santa Cruz Biotechnology), and anti-human hnRNPA1͞A2 (provided by G. Dreyfuss and W. Rigby, University of Pennsylvania, Philadelphia, and Dartmouth Medical School, Hanover, NH, respectively). Cell extracts from the patient with HVDRR and the control subject were subjected to electrophoresis on 10% SDS͞PAGE and transferred to nitrocellulose membranes. Western and Southwestern analyses were performed as described (23) .
Results

Suppression of RXR-VDR-Mediated Transactivation in HVDRR Cell
Lines. We have reported a patient with a classical HVDRRII phenotype including alopecia who presented with apparently normal VDR expression (24) . Transfection of VDR cDNA from the patient into receptor-deficient (human) CV-1 cells resulted in normal transactivation in response to 1,25(OH) 2 D 3 (24) . These data suggested that an extra-VDR factor was interfering with the nuclear translocation and transactivation of endogenous VDR in cells from this patient. To investigate this further, promoter-reporter assays were carried out by using normal and HVDRR fibroblasts as transfection recipients (Fig. 1) . Data confirmed the suppression of VDRE-mediated transactivation in HVDRR cells in the presence or absence of wild-type VDR. Furthermore, in contrast to control cells, HVDRR fibroblasts showed no induction of luciferase activity after treatment with 10 nM 1,25(OH) 2 D 3 .
Vitamin D Resistance in HVDRR Cells Is Associated with Antagonism of VDR-RXRE-RE Complex Formation.
Based on data shown in Fig. 1 , we hypothesized that cells from the patient with HVDRR constitutively overexpress a nuclear protein that competes with the VDR-RXR for binding to heterodimer cis recognition sequences. To test this hypothesis subsequent assays were carried out by using Epstein-Barr virus-transformed HVDRR and control B-lymphocytes, which could be cultured in large volumes to facilitate maximal protein recovery from NEs. We have reported that both fibroblasts and B-lymphocytes from the patient with HVDRR show abnormal nuclear localization of VDR when compared with an age-and sex-matched control (24) . In further studies using only B-lymphocytes we were able to demonstrate the functional significance of these events by comparing the effects of 1,25(OH) 2 D 3 on control and HVDRR cell proliferation. Results in Fig. 2A incubating recombinant human VDR and RXR with an idealized 3 nucleotide-spaced direct repeat VDRE (VDRE-DR3) probe in the presence or absence of increasing amounts of NE from control or HVDRR cells (Fig. 2B) . Data showed that addition of the HVDRR NE competitively displaced RXR-VDR binding to the VDRE in a dose-dependent fashion. In contrast, NEs from control cells were without effect. This observation was confirmed by densitometric analysis of EMSA band density (Fig. 2C) .
Identification of an REBiP in NEs from HVDRR Cells. Further EMSAs were then carried out in the absence of exogenously added recombinant VDR and RXR. Data (Fig. 3) indicated that NEs from HVDRR cells contained a protein(s) that retarded the mobility of labeled VDRE-DR3 (cis sequence AGGTCAcag-AGGTCA; Fig. 3A Left) . A similar observation was made when the highly homologous consensus RXRE was used as probe (cis sequence AGGTCAgAGGTCA; Fig. 3A Right) . The presence of this RE complex was specific for the NE of the patient with HVDRR as equimolar concentrations of the control NE did not retard the VDRE or RXRE in this fashion. Likewise, the RXRE binding complex was not observed in other vitamin D-responsive cell lines such as Old World primate Rhesus monkey breast cells, Colobus lymphocytic cells, or MCF-7 human breast cancer cells (data not shown). Neither the mobility nor the intensity of the retarded HVDRR complex was altered by antihuman RXR or VDR Abs (Fig. 3B) , and HVDRR cells showed apparently normal (i.e., wild-type) levels of RXR␣ and RXR␤ expression (Fig. 3C) . Furthermore, preincubation of NEs with 100 nM 1,25(OH) 2 D 3 , retinoic acid (RAR ligand), or 9-cis retinoic acid (RXR ligand) also had no effect on the mobility or intensity of the HVDRR complex (data not shown). These observations confirmed that neither RXR, VDR, nor their respective ligands participated in retardation of the RE probe by HVDRR NEs.
Hormone RE Specificity of the HVDRR EMSA Complex. The cis element specificity of the HVDRR EMSA complex was assessed by competition analyses (Fig. 4) . Data confirmed that RXRE and VDRE competed out the hormone RE-binding complex. An AGGTCA half-site corresponding to the chicken ovalbumin upstream promoter-transcription factor cis element also acted as a competitor (data not shown). However, consensus sequences for other types of cis elements such as the ERE showed no displacement of the RE binding complex (Fig. 4) . nent(s) was confirmed by using HVDRR NEs that had been digested by trypsin. Unlike untreated HVDRR extracts, these preparations were unable to compete out the EMSA complex formed by recombinant VDR-RXR (Fig. 5A) . In studies of steroid hormone resistance in NWPs, we have demonstrated the presence of hnRNPs that are capable of squelching VDREmediated transactivation by acting as REBiPs (23) . We therefore reasoned that a similar protein could also be associated with aberrant VDRE function in the HVDRR cells. Data (Fig. 5B) indicated that VDRE probe binding by HVDRR NEs was competed away by the addition of anti-hnRNPA1 and anti-hnRNPA2 Ab. These data suggested that, in a fashion similar to that in NWP cells, HVDRR cells expressed an REBiP capable of interacting with the VDRE.
Characterization of the REBiP by Western blot analysis showed increased expression of hnRNPA1 and hnRNPA2 immunoreactive proteins in HVDRR cells (Fig. 5C ). In subsequent Southwestern blots, NEs from HVDRR and control cells were subjected to SDS͞PAGE, and the separated proteins were analyzed for their ability to bind radiolabeled VDRE probe (Fig.  5D Left) and RXRE probe (Fig. 5D Right) . A VDRE-DR3 and RXRE-reactive protein was observed only in the NEs from the HVDRR cells. In view of the RNA-binding capacity of hnRNPs, further studies were carried out to assess REBiP binding to single-stranded nucleotide sequences. HVDRR NEs were incubated with a single-stranded radiolabeled DNA probe consisting of the upper strand of the RXRE. Data (Fig. 5E ) indicated that the resulting REBiP complex could be competed out only by using an excess of unlabeled single-or double-stranded RXREs. To confirm the functional link between this and VDR-mediated transactivation, further reporter studies were carried out by using the VDR-positive human kidney cell-8 cell line cotransfected with expression constructs for human hnRNPA1 or hnRNPA2, and the NWP hnRNPs VDRE-BP1 and VDRE-BP2, which show strong homology to human hnRNPA1 and hnRNPA2, respectively (23) . In the absence of exogenous 1,25(OH) 2 D 3 , all four REBiPs suppressed basal VDRE transcription, with hnRNPA1 showing the strongest response (Fig. 6A) . The ability of REBiPs to squelch hormone-induced transcription was confirmed in cultures treated with 10 nM 1,25(OH) 2 D 3 . Both human and NWP REBiPs suppressed but did not completely block the stimulation of VDRE-luciferase activity, with VDRE-BP1 and hnRNPA1 having the greatest effect (Fig. 6B) . This result contrasts studies using an ERE-reporter construct in which both human and NWP REBiP expression constructs were without effect (data not shown).
Discussion
Vitamin D-resistant rickets currently encompasses two distinct disorders, HVDRRI and HVDRRII. HVDRRI is a rare autosomal recessive disorder in which patients harbor an inactivating mutation of the gene encoding the enzyme 25-hydroxyvitamin-D-1␣-hydroxylase (26, 27) . Children with this disease present at birth with very low circulating levels of 1,25(OH) 2 D 3 , hypocalcemia, and an inability to normally calcify their developing skeleton. HVDRRII is another rare autosomal recessive disease but in this case the classical phenotype is elevated serum levels of 1,25(OH) 2 D 3 , chronic hypocalcemia, rickets, and sometimes alopecia (28) (29) (30) . In common with other hormone-resistance disorders, HVDRRII is usually associated with abnormal expression and function of a cognate intracellular receptor, in this case the VDR (12) (13) (14) .
In data presented here, we describe a form of human hormone insensitivity that is due to overexpression of a dominantnegative-acting REBiP. In this case the phenotype of vitamin D resistance could not be attributed to mutant forms or abnormal amounts of either the VDR or its principal binding partners, RXR␣ and RXR␤, and there was no clinical evidence for malfunction of other steroid hormone receptors. That REBiP is a DNA-binding protein and not a receptor-binding protein indicates that vitamin D resistance in this patient is not due to abnormal expression of a VDR accessory protein. Thus, the receptor-normal hormone resistance observed in this patient with HVDRRII is clearly different to that recently reported for a patient with androgen insensitivity syndrome (6) . Nevertheless, the patient presented with classical symptoms of HVDRRII, including rickets and alopecia. We have therefore termed this HVDRRIII, with the patient representing the first reported human paradigm for the receptor-positive vitamin D resistance observed in NWPs. In the case of the patient with HVDRRIII and that of NWPs, the underlying cause of insensitivity to 1,25(OH) 2 D 3 seems to be overexpression of an hnRNPA, with both the human (hnRNPA1 and hnRNPA2) and their NWP equivalents (VDRE-BP1 and VDRE-BP2) able to squelch VDRE-mediated transactivation.
The hnRNP family is a collection of more than 20 proteins that contribute to the complex around nascent pre-mRNA and are thus able to modulate RNA processing (10) (11) (12) . Members of the group are characterized by their ability to bind to RNA with limited specificity and they are among the most abundant of all of the nuclear proteins (11) . Despite its function in RNA handling, the precise physiological role of hnRNPs has yet to be fully defined and may include transregulatory effects. Recent studies have shown that the hnRNPs D0B (31), E2BP (32) , and K (33) are able to bind to double-stranded DNA motifs within the complement receptor 2, hepatitis B virus, and c-myc promoters, respectively. In contrast to the data from the HVDRR cells, D0B, E2BP, and K all seem to activate gene transcription, suggesting a distinct function for members of the hnRNPA subgroup. It is therefore interesting to note that recent studies have identified a specific 36-bp target sequence for hnRNPA1 in double-stranded DNA (34) . This sequence shows no overlap with established RNA target sequences for hnRNPA1 but notably includes two adjacent cryptic RXRE half-sites (ggctggtcttgaactcctgA͞GCTCAAA͞GGTGAtcctcc). It is also possible that the dominant-negative actions of the REBiP described here are not solely related to its ability to interact with doublestranded DNA. That the REBiP can also bind to a direct repeat of the AGGTCA half-site motif in single-stranded DNA suggests that its ability to squelch transcription may persist after DNA strand separation (35) . It is therefore intriguing to postulate that eventual dislodgment of hnRNPs during transcription will make these single-strand nucleic acid-binding proteins available for interaction with other nearby cis elements such as the 3Ј end of recently transcribed mRNAs.
That the hypocalcemia and rachitic bone disease in this patient with HVDRR were responsive to high-dose 1,25(OH) 2 D 3 treatment (24) indicated that vitamin D resistance was not absolute but instead was likely to be determined by the relative abundance of the hnRNPA-related R EBiP and competent [i.e., 1,25(OH) 2 D 3 -liganded] RXR-VDR heterodimer present in the target cell. If the balance in cis element binding favored REBiP, either because of a relative abundance of this protein and͞or relative lack of the competitive RXR-VDR, then one would predict a 1,25(OH) 2 D 3 -reversible vitamin D-resistant phenotype in vivo. In fact, this prediction was compatible with the response of the patient to treatment with high-dose 1,25(OH) 2 D 3 ; hypocalcemia and rachitic bone disease were corrected as long as the serum 1,25(OH) 2 D 3 level remained high (24) . These data also suggest that it is the VDRE-DR3 cis element which legislates the antirachitic action of the hormone in bone. In contrast, failure of the alopecia of the patient to be improved with an increase in serum 1,25(OH) 2 D 3 levels suggests that (i) the VDRE-DR3 does not participate in control of genes rendering the hairless phenotype; (ii) maternal levels of 1,25(OH) 2 D 3 are not high enough for fetal hair development; and͞or (iii) as suggested by previous data from patients with HVDRR and VDR-ablated animals, the role of 1,25(OH) 2 D 3 -VDR in hair follicle development involves a prenatal mechanism. That the REBiP complex could not be competed-out with an ERE or YY1-RE suggests that the hnRNPA family has greater specificity for direct repeat half-sites. This observation is supported further by the elucidation of a double-stranded DNA target sequence for hnRNPA1 that includes two cryptic direct repeat half-sites (35) . Furthermore, studies from our own group have shown that the ERE-BP in NWP belongs to the distinct hnRNPC family, which is likely to have an entirely different target sequence on double-stranded DNA. Collectively, these observations provide some explanation for the highly specific phenotype observed with the patient with HVDRR. However, in future studies it will be interesting to determine whether related REBiPs are associated with other syndromes of human hormone-resistant disease.
The precise mechanism leading to overexpression of the REBiP in the patient with HVDRR remains unclear but presumably involves the inheritance of a mutant allele(s) leading to constitutive overexpression of an REBiP in fetal life. Relatively little is known about the regulation of hnRNPs in mammalian cells. However, hnRNPA1 levels are increased in myeloid progenitor cells expressing the p210 (BCR͞ABL) oncoprotein, in mononuclear cells from patients with chronic myelogenous leukemia blast crisis (36) , and in the early stages of lung cancer (37) . In addition, hnRNPA2 is regulated by the tumorsuppressing von Hippel-Lindau protein, highlighting a potential link with both oncogenesis and oxygen sensing (38) . These factors may not necessarily be implicated in pathophysiology of the patient with HVDRR described in this study, but aberrant expression of REBiPs may provide a potential mechanism for the hormone resistance that is frequently observed in tumor cells. This hypothesis is particularly relevant in the case of vitamin D where previous studies have highlighted resistance to the antiproliferative properties of 1,25(OH) 2 D 3 and its synthetic analogs despite apparently normal expression of VDR (39, 40) . Further analysis of the tissue and disease distribution of hnRNPs may help to provide a new insight to this problem.
